Molecular Pathways Engaged by Immunomodulatory Agents in Monoclonal Gammopathy-Associated Pure Red Cell Aplasia Rescue

Molecular Pathways Engaged by Immunomodulatory Agents in Monoclonal Gammopathy-Associated Pure Red Cell Aplasia Rescue

Bibliographic Details
Main Author:	Rakesh Verma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-08-01
Series:	Frontiers in Oncology
Subjects:	MGUS multiple myeloma IMiDs immunomodulation ikaros (IKZF1) CRBN
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.01490/full

Similar Items

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
by: Marco Cippitelli, et al.
Published: (2021-01-01)

Design, synthesis, and biological evaluation of a novel series of 2-(2,6-dioxopiperidin-3-yl)isoquinoline-1,3(2H,4H)-dione derivatives as cereblon modulators
by: Yilin Liu, et al.
Published: (2022-12-01)

Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
by: Basudev Chowdhury, et al.
Published: (2024-03-01)

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
by: Matteo Costacurta, et al.
Published: (2021-11-01)

The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
by: Kibata K, et al.
Published: (2019-07-01)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
by: Tingting Jiang, et al.
Published: (2022-12-01)

Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients
by: Widad Tahiru, et al.
Published: (2022-02-01)

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
by: Piotr Kulig, et al.
Published: (2023-02-01)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
by: Shih-Feng Cho, et al.
Published: (2021-12-01)

Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
by: Enrico Milan, et al.
Published: (2023-08-01)

Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury
by: Daniela Lecca, et al.
Published: (2023-03-01)

Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies
by: Ivana Lagreca, et al.
Published: (2023-02-01)

Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
by: Oliver C. Lomas, et al.
Published: (2020-06-01)

Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies
by: Vanessa Innao, et al.
Published: (2021-05-01)

Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
by: Antonio Gidaro, et al.
Published: (2022-05-01)

Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells
by: Harish Kumar, et al.
Published: (2022-05-01)

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury
by: Shih Chang Hsueh, et al.
Published: (2022-09-01)

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors
by: Yu Wang, et al.
Published: (2024-01-01)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
by: Damian Mikulski, et al.
Published: (2022-10-01)

Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma
by: Sarah eTete, et al.
Published: (2014-06-01)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
by: Katherine O. Kopp, et al.
Published: (2023-04-01)

CURRENT ROLE OF RADIATION THERAPY FOR MULTIPLE MYELOMA
by: Giampaolo eTalamo, et al.
Published: (2015-02-01)

Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens
by: Jean Harb, et al.
Published: (2021-02-01)

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
by: Arthur Bobin, et al.
Published: (2021-10-01)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
by: Daisuke Goto, et al.
Published: (2020-01-01)

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
by: David F. Moreno, et al.
Published: (2021-10-01)

A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
by: Lifeng Li, et al.
Published: (2020-09-01)

The “Undetermined Significance” of <sup>18</sup>F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
by: Giorgio Treglia, et al.
Published: (2021-08-01)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
by: James Ackley, et al.
Published: (2021-09-01)

The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
by: Ivana Lagreca, et al.
Published: (2022-05-01)

Low knowledge and awareness of monoclonal gammopathy of undetermined significance (MGUS) among general practitioners
by: Charlene M. McShane, et al.
Published: (2019-05-01)

<i>IKZF1</i> Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia
by: Jonathan Paolino, et al.
Published: (2024-01-01)

Familial Immune Thrombocytopenia Associated With a Novel Variant in IKZF1
by: Panida Sriaroon, et al.
Published: (2019-04-01)

Geographic Prevalence Patterns and Modifiable Risk Factors for Monoclonal Gammopathy of Undetermined Significance
by: Karina P. Verma, et al.
Published: (2023-11-01)

Case report: IKZF1-related early-onset CID is expected to be missed in TREC-based SCID screening but can be identified by determination of KREC levels
by: Christofer Äng, et al.
Published: (2023-09-01)

Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy
by: Thayne Woycinck Kowalski, et al.
Published: (2021-06-01)

Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
by: Hao Guo, et al.
Published: (2022-10-01)

Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
by: Daniela Damasceno, et al.
Published: (2021-03-01)

Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of unknown significance: A case report
by: Garima Gupta, et al.
Published: (2024-02-01)